Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) secured EU marketing authorization for its PD-1 inhibitor, Serplulimab, in combination with carboplatin and etoposide for treating extensive-stage small cell lung cancer.
The approval grants the drug centralized marketing rights across all EU member states, Iceland, Liechtenstein and Norway, according to a Wednesday filing with the Shanghai bourse.
Shares of the pharnaceutical company rose 1% in recent trade on the Shanghai bourse.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。